![]() | |
Company type | Public limited company |
---|---|
ISIN | GB00BMX86B70 |
Industry | |
Predecessors | |
Founded | 18 July 2022 |
Headquarters | Weybridge, England, United Kingdom |
Area served | Worldwide |
Key people |
|
Products |
|
Brands | |
Revenue | ![]() |
![]() | |
![]() | |
Total assets | ![]() |
Total equity | ![]() |
Number of employees | 24,000 (2024) [2] |
Subsidiaries | Haleon Pakistan |
Website | www |
Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England. [3] It is one of the largest consumer healthcare businesses in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers and Centrum vitamins. [4] The company was projected to be a global leader in over the counter medicines with a 7.3 per cent market share in 2022. [5]
Haleon was established on 18 July 2022 as a corporate spin-off from GSK. [6] Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange.
GSK and Pfizer merged their consumer healthcare businesses in 2019. [7] [8] GSK owned just over two thirds of the joint venture, and Pfizer held the remainder. [7]
Annual sales amounted to around £10 billion across 120 markets in 2020. [5]
GSK announced plans to spin off Haleon in 2022, in order to give the "tired drugmaker extra focus and firepower by gearing up and hiving off the consumer division," according to Reuters. [9]
Unilever offered £50 billion for the business in 2022, in a bid which GSK rejected. [10] Nestlé examined the possibility of a bid in conjunction with Reckitt. [11]
In October 2023, GSK reduced its ownership share in Haleon to just over 7.4 per cent, [12] and again in January 2024 down to 4.2 per cent. [13]
The Lamisil antifungal brand was sold to Karo Healthcare AB for £235 million in August 2023; the transaction was completed in November 2023. [14] [15]
The ChapStick lip care brand was sold to Yellow Wood Partners for £401 million in 2024. [16]
In March 2024, Pfizer reduced its stake in Haleon from 32 per cent to 24 per cent by selling 630 million shares in a public offering. [17]
In April 2024 Haleon announced that it planned to close its factory in Maidenhead. [18] Toothpaste manufacturing would be relocated to Slovakia, with mouthwash production outsourced to a third party. [19]
In September 2024, the company completed the sale of its non-US Nicotine Replacement Therapy business to Dr. Reddy's Laboratories in a deal worth £458 million. [20]
In March 2025, Pfizer sold its entire stake in Haleon for approximately £2.5 billion ($3.24 billion), marking its complete exit from the consumer healthcare firm it helped create through its 2019 joint venture with GSK. [21] [22] [23]
Oral health accounted for 28.5 percent of revenue in 2021. [24]
Sir Dave Lewis is chairman, with Brian McNamara as chief executive. [25]
Brands include: [26]
{{cite journal}}
: Cite journal requires |journal=
(help){{cite web}}
: |last=
has generic name (help)